c v i . s ta n fo rd .e d u | 1

SPRING 2019 Donate to the CVI

CVI Welcomes 2019 Summer Undergraduate Interns

9Over 500 people attended the fourth annual Stanford Drug Discovery Symposium. The attendees were a mix of industry and academia. The meeting was a highly successful two days of thought-provoking presentations. It was an opportunity to interact with federal and foundation policy makers, leaders from major pharmaceutical companies, and pioneers in drug discovery research. Dr. John Martin was awarded the Lifetime Achievement Award. More on page 2.

Natasha AuerUC Santa BarbaraMentor: Dr. de Jesus PerezJulianne BallonUniversity of GuamMentor: Dr. Fishbein

Christian Beke Onana Univ. of Houston DtnMentor: Dr. Hiesinger

Lily ChengUniv. Mich. Ann ArborMentor: Dr. Sayed

Beatrice Choi Stanford UniversityMentor: Dr. Rhee

Lauren D'Amico Univ. of WashingtonMentor: Dr. Bernstein

Nashielli Diaz Tufts UniversityMentor: Dr. Karakikes

Gabriela Escobar Stanford UniversityMentor: Dr. Sean Wu

Breauna Franklin Clemson UniversityMentor: Dr. Sayed

Roberto Guzman Univ. of Puerto RicoMentor: Dr. Yuan

Kelly Lancaster UC Berkeley Mentor: Dr. Liao

Rachel Lippman Cornell University Mentor: Dr. Mercola

Joseph Lohmann Univ. of Pennsylvania Mentor: Dr. Priest

Sarah Madira Cal State Los Angeles Mentor: Dr. Anson Lee

Rachael Mezynski North Carolina State Mentor: Dr. Joe Wu

Taylor Montiel San Jose City CollegeMentor: Dr. Woo

Raquel Racelis San Francisco State Mentor: Dr. Red-Horse

Samantha Roach Spelman CollegeMentor: Dr. Shudo

Caydin Sablan Univ. of San FranciscoMentor: Dr. Liao

A diverse group of undergrads from across the country join us to learn about cardiovascular research.

c v i . s ta n fo rd .e d u | 2

On April 22-23, 2019, the fourth annual Stanford Drug Discovery Symposium was held at the Li Ka Shing Center. The meeting featured presentations and panel discussions from federal and foundation policy makers, leaders from major pharmaceutical companies, and pioneers in drug discovery research. There was a Showcase panel event with venture capitalists and leaders from Caribou Biosciences, Immune-Onc Therapeutics, and Appollomics. 2019 Featured Speakers: Anthony Adamis, Genetech; Jeffery Bluestone, Parker Institute; Jim Doroshow, NCI; Brian Druker, Knight Cancer Institute; Victor Dzau, National Acad of Medicine; Peter Fitzgerald, Triventures; Sandra Horning, Genentech; Allan Jones, Allen Institute; Crystal Mackall, Stanford, Parker Institute; Mathai Mammen, Janssen Pharmaceuticals; John C. Martin, Gilead; Peter Marks, FDA; Maria Millan, CIRM; Lloyd Minor, Dean, Stanford Medicine; Andrew Plump, Takeda; John Reed, Sanofi; Alan Sachs, Thermo Fisher; Camille Samuels, Venrock; Randy Schekman, HHMI, UC Berkley, Nobel Prize; Orla Smith, Science Translational Medicine; Young Sohn, Samsung Electronics; Marc Tessier-Lavigne, Stanford President; Sandy Weill, Citigroup; George Yancopoulos, Regeneron PharmaceuticalsMeeting organizers Sanjay Malhotra, Mark Mercola, Kuldev Singh, Joseph C. Wu, Amanda Chase, and David Preston hope you will join us next year, April 20-21 2020, for SDDS 2020.

Participants Adamis, Reed, Horning, Sachs, Shatz, Schekman, Singh, Drucker, Minor, Martin, Milan, Tessier-Lavigne, Wu, Smith, Mammen, Redkar, Dzau, Malhotra, Mercola, Bauchner, and Doroshow

Opening Keynote Address by Dr. Victor Dzau (National Academy of Medicine).

Dr. Paul Berg (right) presented the Lifetime Achievement Award to Dr. John Martin (left).

Showcase with A. Adamis (Genentech), W. Myers, Jr. (Myers Ventures), S. Kanner (Caribou), S. Redkar (Appollomics), C. Liao (Immune-Onc), C. Samuels (Venrock), and R. Shriram (Sherpalo).

27 poster presentationsGovernment and Philanthropy session. J. Doroshow (NIH), A. Jones (Allen Institute), S. Weill (Citigroup), and M. Millan (CIRM).

Dean Minor and President Tessier-Lavigne discuss Stanford innovative medicine.

SDDS 2019 Highlights

c v i . s ta n fo rd .e d u | 3

Keynotes: Paul Yock, Dan RaderConfirmed Speakers: Daria Mochly-Rosen, Sarah Heilshorn , Saman

Nazarian, Will Heisinger, Yasuhiro Shudo, Shipra Arya, Tom Cappola, Kiran Khush, Ron Witteles, Bonnie Ky, Marlene Rabinovitch, Vinicio de Jesus

Perez, Ed Morrissey, Rajan Jain, James Priest, Kristy Red-Horse, Helen Blau, Ioannis Karakikes, Ngan Huang, Kiran Musunuru, Dan Kelly, Ronglih Liao,

Zoltan Arany, Nick Leeper, Scott Damrauer, Elsie Ross

Stanford-UPenn Cardiovascular Research ConferenceNovember 4 - 5, 2019, Li Ka Shing Center, Stanford

E-Cigarette use, flavorings, may increase heart disease risk, study findsBy Krista Conger

The flavoring liquid for electronic cigarettes, or e-cigarettes, may increase the risk of cardiovascular disease when inhaled, according to a study led by researchers at the School of Medicine. The scientists investigated the effect of the e-liquids on cells called endothelial cells that line the interior of blood vessels. They found that, when grown in a laboratory, endothelial cells exposed to the e-liquids — or to blood collected from e-cigarette users shortly after vaping — are less viable and exhibit significantly increased levels of molecules implicated in DNA damage and cell death. The cells are also less able to form new vascular tubes and to migrate and participate in wound healing. The severity of the damage, aspects of which occur even in the absence of nicotine, varies among popular flavors, the researchers said. Cinnamon and menthol were found to be particularly harmful. “Until now, we had no data about how these e-liquids affect human endothelial cells,” said Joseph Wu, MD, PhD, director of the Stanford Cardiovascular Institute and professor of cardiovascular medicine and of radiology. “This study clearly shows that e-cigarettes are not a safe alternative to traditional cigarettes. When we exposed the cells to six different flavors of e-liquidwith varying levels of nicotine, we saw significant damage. The cells were less viable in culture, and they began to exhibitmultiple symptoms of dysfunction.”

The researchers studied human endothelial cells generated in the laboratory from what are called induced pluripotent stem cells, or iPS cells. Human iPS cells can become many different cell types, and they provide an ideal way for researchers to closely study cells that would be difficult to isolate directly from a patient.

This study was the first to use endothelial cells derived from iPS cells to directly investigate the effect of e-liquids with and without nicotine on their viability and function.

A paper describing the findings was published online May 27 in the Journal of the American College of Cardiology. Wu is the senior author. Former postdoctoral scholars Won Hee Lee, PhD, now an assistant professor at the University of Arizona, and Sang-Ging Ong, PhD, now an assistant professor at University of Illinois-Chicago, are the lead authors.

“One in five high school students have tried e-cigarettes, perhaps because they feel they are relatively safe,” Lee said. “But we found the e-liquids caused changes in the endothelial cells that are closely related to those seen during the development of cardiovascular disease.”

The researchers compared the levels of nicotine in the blood serum of people after they had vaped e-cigarettes with the levels in people who smoked traditional cigarettes. They found that the amounts of nicotine in the blood were similar between the two groups after 10 minutes of smoking at a constant rate.

“When you’re smoking a traditional cigarette, you have a sense of how many cigarettes you’re smoking,” Wu said. “But e-cigarettes can be deceptive. It’s much easier to expose yourself to a much higher level of nicotine over a shorter time pe-riod. And now we know that e-cigarettes are likely to have other significantly toxic effects on vascular function as well. It’simportant for e-cigarette users to realize that these chemicals are circulating within their bodies and affecting their vascular health.”

This work was also covered by The New York Times, Business Insider, CNN, CBS, AP, Fox, and Yahoo.Source: http://med.stanford.edu/news/all-news/2019/05/e-cigarette-use-and-flavorings-may-increase-heart-disease-risk

Won Hee Lee, PhD

tinyurl.com/StanfordPennCV

c v i . s ta n fo rd .e d u | 4

Women leaders in cardiac transplantation

Source: http://med.stanford.edu/cvi/mission/news_center/articles_announcements/sharon-hunt-reflects-on-women-leaders-in-cardi-ac-transplantation.html

The first successful heart transplant in the United States was performed at Stanford in 1968. Chief Surgeon Norman Shumway replaced the diseased heart of Mike Kasperak, a retired steelworker. He survived for only 15 days. However, due to innovations in post-transplant patient care, today heart transplantation has become commonplace, and the surgery ensures patients a relatively high quality of life for years and often decades after surgery.

Sharon Hunt, MD, was a medical student at Stanford in 1968. By the time she finished her cardiology fellowship at Stanford, patient survival rates had begun to improve, and Hunt was one of four cardiologists asked to provide long term care for transplant recipients. Now a Professor Emerita of Cardiovascular Medicine at Stanford, Hunt is well known for her innovations in the care of patients after heart transplantation.

In an article published in February 2019 in Circulation, Hunt discusses the impact of women leaders in Cardiac Transplantation.

Currently 26% of board-certified transplantation care specialists in the US are women, a ratio that, though not equal, is far better than many other cardiac subspecialties. Hunt is quick to point out that the often-credited work-life balance and flexible hours are not the reason for the relatively high number of women in this subspecialty. She instead points to the fact that “Women have been in the field from the beginning, continue to be successful as specialists, hold leadership positions and have many relatable role models.”

by Megan Mayerle, PhD

Sharon Hunt, MD

Stanford CVI: At the forefront of cardiovascular researchRecognized for excellence, the Stanford University School of Medicine has long been at the forefront of cardiovascular research, patient care, and discovery. The Stanford Cardiovascular Institute (CVI) serves as an interdisciplinary nucleus concentrating and coordinating the activities of scientists, bioengineers, educators, and physicians committed to improving cardiovascular health and to training the next generation of leaders in cardiovascular medicine. The history and mission, research, strengths, and future directions of the CVI are featured in Circulation Research in May, 2019, authored by Joseph Wu, MD, PhD, Joseph Woo, MD, Megan Mayerle, PhD, Robert Harrington, MD, and Thomas Quertermous, MD.Source: https://www.ahajournals.org/doi/full/10.1161/CIRCRESAHA.119.310761?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed

Congenital heart defects increase risk of heart problems later in life

An infant born with a relatively simple heart defect is far more likely to develop heart problems as an adult, researchers at the Stanford University School of Medicine have discovered.

The risk is so great that someone born with a heart defect who has a heart-healthy lifestyle is twice as likely to develop heart problems as someone born without a defect who has a heart-averse lifestyle.

“All of us in cardiology recognize that people with complex disease need follow-up care throughout their lives," said James Priest, MD, assistant professor of pediatric cardiology. “But for the simple problems, we’ve been thinking that once you close the hole or fix the valve, these patients are good to go.”

The research findings suggest that the medical community should watch adults who were born with heart defects — even minor ones — more carefully. Medications and lifestyle changes may help prevent or delay major heart conditions, such as heart attacks, stroke, heart failure and atrial fibrillation.

A paper describing the research was published Feb. 28 in Circulation. Priest is the senior author; Priyanka Saha, a student at Harvard Medical School who was a research fellow at Stanford from 2017 to 2018, is the lead author.

Source: http://med.stanford.edu/news/all-news/2019/02/congenital-heart-defects-increase-risk-of-later-heart-problems.html

James Priest, MD

by Mandy Erickson

Grants and Awards

c v i . s ta n fo rd .e d u | 5

Donate to the Stanford Cardiovascular InstituteThe Institute currently consists of over 240 faculty members representing physicians, surgeons,

engineers, basic and clinical researchers. The Institute's mission is integrating fundamental

research across disciplines and applying technology to prevent and treat cardiovascular

disease. To support cardiovascular research and education at CVI, please contact: Joseph C. Wu, MD, PhD, CVI Director at joewu@stanford.edu or Cathy Hutton, Senior Associate Director,

Medical Center Development at cathy.hutton@stanford.edu. For more information: http://med.

stanford.edu/cvi/support-our-research.html and http://cvi.stanford.eduCathy Hutton, MBAJoseph C. Wu,

MD, PhD

Linda Ottoboni, PhD, FHRS, CCDS, was appointed to the Heart Rhythm Society National Governing Committee.

Kuninobu Kashiyama, MD, received ACC Best Poster Award at the 2019 Annual Scientific Session.

Kevin Cyr was awarded Grand Prize at Stanford Medical School Research Symposium.

Sharon Paige, MD, joined the Department of Pediatrics Instructor Pipeline Program.

Maedeh Zamani, PhD, was awarded an AHA postdoctoral fellowship.

Ji Hye Jung, PhD, was awarded an AHA postdoctoral fellowship.

Mark Nicolls, MD, and Amy Tian, PhD, were awarded an NIH R01 grant to evaluate the role of inflammation in lymphedema.

Sangkyun Cho, PhD, was appointed as a new Cardiovascular Imaging T32 trainee.

Joseph Shrager, MD, received an R01 grant on "A Mechanistic Clinical Trial of JAK Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction".

Nicholas Leeper, MD, received the AHA Established Investigator Award.

Edda Spiekerkoetter, MD, received a Department of Defense grant to address hereditary hemorrhagic telangiectasia.

Helen Blau, PhD, was elected to the American Institute for Medical and Biological Engineering (AIMBE).

Tim Assimes, PhD, 2019 recipient of the AHA Genomic and Precision Medicine and Epidemiology Mid-Career Research Award and Lecturer.

Robert Wirka, MD, was awarded the Irvine H. Page Young Investigator Award at 2019 ATVB.

Jason Lee, MD, elected to the Vascular Surgery Board of the American Board of Surgery.

Fatima Rodriguez, MD, MPH, FACC, was awarded an NIH K01 on "SURPASS (Statin Use and Risk Prediction of Atherosclerotic Cardiovascular Disease in minority Subgroups)".Ngan Huang, PhD, was awarded a Department of Vetern Affairs grant on "Engineering Vascularized Skeletal Muscle for Treatment of Volumetric Muscle Loss", and an Alliance for Regenerative Rehabilitation and Rsearch Training grant on "Stretchable Tissue Chips for Customizable Rehabilitative Microenviornments".

5

2018 Manuscript Award Winners

c v i . s ta n fo rd .e d u | 6

Ke Yuan, PhD

Loss of Endothelium-Derived Wnt5a is Associated with Reduced Pericyte Recruitment and Small Vessel Loss in Pulmonary Arterial Hypertension. Yuan K, Shamskhou EA, Orcholski ME, Nathan A, Reddy S, Honda H, Mani V, Zeng Y, Ozen MO, Wang L, Demirci U, Tian W, Nicolls MR, de Jesus Perez VA. Circulation. 2019 Apr 2;139(14):1710-1724.

Lab: Vinicio de Jesus Perez, MD

Darshan Trivedi, PhD

Deciphering the Super Relaxed State of Human b-cardiac Myosin and the Mode of Action of Mavacamten from Myosin Molecules to Muscle Fibers. Anderson RL, Trivedi DV, Sarkar SS, Henze M, Ma W, Gong H, Rogers CS, Gorham JM, Wong FL, Morck MM, Seidman JG, Ruppel KM, Irving TC, Cooke R, Green EM, Spudich JA. PNAS 2018 Aug 28;115(35):E8143-E8152.

Lab: James Spudich, PhD

AI identifies risk of cholesterol-raising genetic diseaseA new algorithm can determine whether a patient is likely to have a cholesterol-raising genetic disease that can cause early, and sometimes fatal, heart problems, reports a new study conducted by researchers at the Stanford University School of Medicine and their collaborators. The disease, known as familial hypercholesterolemia (FH), is often misdiagnosed as garden-variety high cholesterol. “We think that less than 10 percent of individuals with FH in the United States actually know that they have it,” said Joshua Knowles, MD, PhD, assistant professor of cardiovascular medicine at Stanford. "It’s a serious oversight, because an FH patient with high cholesterol is three times more likely to develop early heart disease than someone who has high cholesterol but not FH. A person with FH faces 10 times the risk of heart disease as someone with normal cholesterol."

Knowles and Nigam Shah, MBBS, PhD, associate professor of medicine and of biomedical data science, have come up with a solution to help catch more cases of FH: a computer algorithm that flags patients who are likely to have the disease. In test runs of the algorithm, it correctly identified 88 percent of the cases it screened. Theoretically, if the algorithm were used in a clinic, any patient it flagged as having FH could undergo further genetic testing to verify the algorithm’s calculation.

A paper describing the research was published in npj Digital Medicine. Shah and Knowles, who is the director of the FH clinic at Stanford Health Care’s Center for Inherited Cardiovascular Disease, share senior authorship. Juan Banda, PhD, a former research scientist at Stanford, is the lead author. The project is part of a larger initiative called Flag, Identify, Network, Deliver FH, or FIND FH, a collaborative effort involving Stanford Medicine and established by the nonprofit Familial Hypercholesterolemia Foundation that aims to identify and engage individuals and families affected by the disease by leveraging machine learning and big data.

Now, Knowles and Shah are working on ways to implement the algorithm in doctors’ offices. The work is an example of Stanford Medicine’s focus on precision health, the goal of which is to anticipate and prevent disease in the healthy and precisely diagnose and treat disease in the ill.Source: http://med.stanford.edu/news/all-news/2019/04/ai-identifies-risk-of-cholesterol-raising-genetic-disease.html

Jingjing Li, PhD

Decoding the Genomics of Abdominal Aortic Aneurysm. Li J, Pan C, Spin JM, Deng A, Leung LLK, Dalman RL, Tsao PS, Snyder M. Cell 2018 Sept 6; 174(6):1361-1372.

Lab: Michael Snyder, PhD; Phil Tsao, PhD

Ning Ma, PhD

Determining the Pathogenicity of a Genomic Variant of Uncertain Significance using CRISPR/Cas9 and Human-Induced Pluripotent Stem Cells. Ma N, Zhang JZ, Itzhaki I, Zhang SL, Chen H, Haddad F, Kitani T, Wilson KD, Tian L, Shrestha R, Wu H, Lam CK, Sayed N, Wu JC. Circulation. 2018 Dec 4;138(23):2666-2681.

Lab: Joseph Wu, MD, PhD

Takeshi Nishi, MD

Fractional Flow Reserve and Quality-of-Life Improvement After Percutaneous Coronary Intervention in Patients with Stable Coronary Artery Disease. Nishi T, Piroth Z, De Bruyne B, Jagic N, Möbius-Winkler S, Kobayashi Y, Derimay F, Fournier S, Barbato E, Tonino P, Jüni P, Pijls NHJ, Fearon WF. Circulation. 2018 Oct 23;138(17):1797-1804.

Lab: William Fearon, MD; Peter Fitzgerald, MD, PhD

David Paik, PhD

Large-Scale Single-Cell RNA-Seq Reveales Molecular Signatures of Heterogeous Populations of Human Induced Pluripotent Stem Cell-Derived Endothelial Cells. Paik DT, Tian L, Lee J, Sayed N, Chen IY, Rhee S, Rhee JW, Kim Y, Wirka RC, Buikema JW, Wu SM, Red-Horse K, Quertermous T, Wu JC. Circulation Reserach. 2018 Aug 3;123(4):443-450.

Lab: Joseph Wu, MD, PhD

Joshua Knowles, MD, PhD

by Hanae Armitage

c v i . s ta n fo rd .e d u | 7

The Stanford Children’s Health Betty Irene Moore Children’s Heart Center is inaugurating a major initiative in Basic Science and Engineering (BASE). Scientists will be appointed to the Children’s Heart Center and as tenure track Assistant, Associate or Full Professors in the Basic Science or Engineering Departments of Stanford University. Our goal is to leverage cutting edge research to address the challenges we face in children with heart disease.

Inquiries to: Marlene Rabinovitch, MD c/o Michelle Fox, RA mfox1@stanford.edu. http://www.med.stanford.edu/base

Recruitment for Assistant, Associate, or Full Professor, Stanford BASE Initiative

Modeling patient-specific responses to common calcium channel blocker using iPS Cells by Megan Mayerle

Advances in treatment strategies and therapeutics allow individuals with chronic conditions a high quality of life. The symptoms of a wide variety of diseases can be mitigated simply by taking a pill. Many patients with hypertension are prescribed calcium channel blockers (CCBs) to control their blood pressure, which they take for the rest of their life. Although the acute effects of CCBs are well understood, very little is known about how these drugs impact cardiomyocyte physiology and gene expression patterns. Calcium is very important to heart cell function, and it is possible that CCBs could alter various cardiac cellular processes.

In a paper recently published in Circulation Research, Stanford Cardiovascular Institute researchers led by instructor Chi Keung Lam used cardiomyocytes made from induced pluripotent stem cells (iPSC-CMs) isolated from three individuals to understand how four commonly prescribed CCBs (nifedipine, amlodipine, diltiazem, and verapamil) affected cardiomyocyte function in different people.

“iPSC technology allows us the opportunity to study how individual drugs will affect each patient, so we can decide on optimized, individualized treatment strategies”, Lam says.

Because they used multiple iPSC-CM cell lines isolated from different patients, Lam and colleagues were able to identify patient specific responses to each of the four CCBs tested. They were also able to determine a drug-specific gene expression signature for each CCB. Combining these findings, Lam and colleagues were able to pinpoint specific genes that could be used to predict how well individual hypertrophic cardiomyopathy patients would respond to verapamil, a specific CCB.Source: http://med.stanford.edu/cvi/mission/news_center/articles_announcements/patient-specific-responses-to-extended-use-of-calcium-channel-bl.html

Chi Keung Lam, PhD

Understanding metabolism and maturation of iPSC cardiomyocytesby Amanda Chase, PhD

Human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) have been shown to be a great tool for modeling CVD and drug screening, and are also being used for transplantation into injured heart muscle as a potential therapy. A limitation to the use of these iPSC-CMs is that they are considered to be immature, similar to early human embryonic cardiomyocytes. To fully realize the potential of iPSC-CMs, they need to be more mature. It has been shown that iPSC-CMs show maturation over a longer period of time in culture, but no work has been done to characterize events that control transitions of cardiac cells during developmental progression. In a paper recently published in Circulation Research, Stanford Cardiovascular Institute researchers sought to understand functional and metabolic transitions of cardiac cells during development, which could provide insight into maturing iPSC-CMs.

These efforts were led by Antje Ebert, Ph.D., who is now a group leader at the University of Goettingen, Medical Center in Germany. They used iPSC-CMs that were kept in culture for different lengths of time (early, medium, and late), and then looked at network pathways at each time point and comparing between them. They were able to describe a novel mechanism governing metabolic output during long-term culture. Dr. Ebert explains that “this study shows that iPSC-CMs can serve as a model for studying human cardiomyocyte development progression during maturation. We also show that modulation of cardiomyocyte metabolism during development affects contractility of cardiomyocytes.” That is an important distinction for mature CMs. “Our study provides options for maturing iPSC-CMs, which is extremely useful for disease modeling, drug testing, and future regenerative approaches,” explains senior author Joseph C. Wu, M.D., Ph.D., Director of Stanford Cardiovascular Institute.Source: http://med.stanford.edu/cvi/mission/news_center/articles_announcements/understanding-metabolism-and-maturation-of-ipsc-cardio-myocytes.html

Antje Ebert, PhD

c v i . s ta n fo rd .e d u | 8

Shadi Bagherzadeh, MDMentor: Francois Haddad, MD

'Resting Blood Pressure in 2881 Athletes Aged 9-35 Years of Age and the Relation to Sex, Age,

Body Size and Afro-American Descent'American Collee of Cardiology (ACC.19)

March 17, 2019New Orleans, LA

Adam Bush, PhDMentor: Shreyas Vasanawala, MD, PhD

'Contiguous Rosette Echoes iN Single Highly Accelerated Acquisition (CRENSHAA) for Rapid,

Motion Resolved T2* Quantification'Society of Cardiovascular Magnetic Resonance

February 6-9, 2019Seattle, WA

Joscha Mulorz, MDMentor: Philip Tsao, PhD

'E-cigarette Vapor Accelerates Abdominal Aortic Aneurysm In Mice'

AHA Vascular Discovery: From Genes to Medicine Sciencific Sessions 2019

May 14-16, 2019Boston, MA

Takeshi Nishi, MDMentor: Peter Fitzgerald, MD, PhD

'Intravascular Ultrasound Predictors of 4-Year Clinical Outcomes Following ABSORB

Bioresorbable Scaffold Implantation: Insights from the ABSORB Japan Trial'

The American College of Cardiology's 68th Annual Scientific Sesseion

March 16-18, 2019New Orleans, LA

Pavlos Tsantilas, MDMentor: Nicholas Leeper, MD

'Chitinase-3-like Protein 1 is an Inhibitor of Vascular Smooth Muscle Cell Dedifferentiation

in Advanced Atherosclerosis'AHA Vascular Discover 2019

May 14-16, 2019Boston, MA

3D nanostructures improve skeletal muscle regeneration by Megan Mayerle, PhD

Our muscles get stronger though repeated cycles of injury and repair. Exercise damages muscle, but at the same time activates muscle stem cells that differentiate into new skeletal muscle fibers, repairing and strengthening the tissue. However, sometimes the amount of damage done to muscle is too much, and, unable to properly heal, chronically inflamed scar tissue forms. In order to heal from this type of injury, the body must not only produce new skeletal muscle cells, it must also make sure that these cells orient properly to contract.

In a study recently published in Communications Biology, Stanford Cardiovascular Institute researchers Karina Nakayama, PhD, Ngan Huang, PhD, and colleagues describe a method to fabricate skeletal muscle using spatially patterned bioengineered scaffolds. These scaffolds help newly formed skeletal cell muscles align, and when implanted into a damaged area, help mice recover from injury.

The researchers created aligned nanofibrillar scaffolds and then seeded them with myoblasts and endothelial cells, the cell types that make up skeletal muscle tissue. The nanofibrillar scaffolds organized the cells, producing long skeletal muscle myotubules capable of contracting strongly and consistently. Alignment also affected cellular gene expression, inducing differential transcriptional pathways that may regulate how engineered muscle behaves.

To test this engineered muscle, the scientists transplanted their aligned engineered skeletal muscle to a site of injury in the mice. The aligned tissue integrated into the site of injury without significant scarring. It also aided in tissue revascularization, which is critical for recovery from injury.

This method shows translational promise, as the researchers were also able to show that human cells aligned on bioengineered scaffolds functioned similarly to the mouse cells and highlights the importance of how cells are positioned in 3D in regenerative medicine approaches.Source: http://med.stanford.edu/cvi/mission/news_center/articles_announcements/3d-nanostructures-improve-skeletal-muscle-regeneration.html

Ngan Huang, PhD

Travel Award Winners

c v i . s ta n fo rd .e d u | 9

Apple Heart Study demonstrates ability of wearable technology to detect atrial fibrillationResearchers from the Stanford University School of Medicine today presented preliminary results of the Apple Heart Study, an unprecedented virtual study with over 400,000 enrolled participants. The researchers reported that wearable technology can safely identify heart rate irregularities that subsequent testing confirmed to be atrial fibrillation, a leading cause of stroke and hospitalization in the United States.

The study was launched with sponsorship by Apple Inc. in November 2017 to determine whether a mobile app that uses data from a heart-rate pulse sensor on the Apple Watch can identify atrial fibrillation. The condition often remains hidden because many people don’t experience symptoms. “The results of the Apple Heart Study highlight the potential role that innovative digital technology can play in creating more predictive and preventive health care,” said Lloyd Minor, MD, dean of the Stanford School of Medicine. “Atrial fibrillation is just the beginning, as this study opens the door to further research into wearable technologies and how they might be used to prevent disease before it strikes — a key goal of precision health.”

The Stanford principal investigators were Mintu Turakhia, MD, associate professor of cardiovascular medicine, and Marco Perez, MD, associate professor of cardiovascular medicine, and the study chair was Kenneth Mahaffey, MD, professor of cardiovascular medicine. Source: http://med.stanford.edu/news/all-news/2019/03/apple-heart-study-demonstrates-ability-of-wearable-technology.html

Single Ventricle SummitOn April 29-30, patients, parents, and distinguished scientists, bioengineers, and clinicians from around the world came together for the Second Annual Stanford Single Ventricle Scientific Summit. This event was an opportunity for synergy across disciplines, with the major focus being on advancing single ventricular science. The summit was organized by: Gail Wright, MD, Erin Hoffmann Medical Director of the Comprehensive Single Ventricle Program, Sean Wu, MD, PhD, Associate Professor of Medicine, and Marlene Rabinovitch, MD, Dwight and Vera Dunlevie Professor of Pediatrics. It was made possible by the Hoffmann Schroepfer Foundation.

Kenneth Mahaffey, MD

Marco Perez, MD Mintu Turakhia, MD

Single Ventricle Summit group

CVI Seed Grant AwardsDue August 1, 2019Eligibility: Stanford Faculty and Instructor members of the CVI (become a member at CVI website).Awards are $15,000 to $40,000 for 1 year and funded in part by the Maternal and Child Health Research Institute and the Steven M. Gootter Foundation. We encourage new interdisciplinary collaborations, work in areas of pediatric and obstetric related research, development of new methods or technology for heart and vascular biology, and research on sudden cardiac death.Questions: David Preston at preston@stanford.edu

Development at the heart of science by Jaclyn M. Jansen

In a recent conversation with Circulation Research, CVI faculty member Sean Wu, MD, PhD, described his development and career as a scientist.

Both in his life and his research, he has taken a uniquely broad and adaptable approach that has helped him become a leader in developmental cardiology.Source: https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.119.315208

Sean Wu, MD, PhD

Leah Backhus, MD, became a newly inducted member of the American Association for Thoracic Surgery (AATS). AATS members are recognized as having a record of distinction within the field and for having made significant contributions towards the treatment of cardiothoracic disease. Dr. Backhus was

also appointed Director-at-Large of the Society of Thoracic Surgeons (STS) and secretary/treasurer of Women in Thoracic Surgery. She is a clinically active surgeon, recenlty received a large VA Merit Award, and is the Thoracic Residency Program Director, thereby epitomizing the "triple threat" academic physician.

Leah Backhus, MD

c v i . s ta n fo rd .e d u | 10

A new landmark clinical trial shows that a drug lowers the risk of kidney failure by a third in people with Type 2 diabetes and kidney disease. “For the first time in 18 years, we have a therapy for patients with Type 2 diabetes and chronic kidney disease that decreases kidney failure,” said Kenneth Mahaffey, MD, professor of medicine at the School of Medicine and co-principal investigator of the trial. “Now, patients with diabetes have a promising option to guard against one of the most severe risks of their condition.” The trial involved 4,401 participants in 34 countries.

The drug, canagliflozin, improves on a nearly two-decades-old therapy that is currently the only treatment approved to protect kidney function in people with Type 2 diabetes. In the trial, canagliflozin also was found to reduce the risk of major cardiovascular events. It has already been approved to lower blood glucose in patients with Type 2 diabetes and to reduce the risk of major adverse cardiovascular events in patients with Type 2 diabetes and existing heart disease.

A paper describing the findings of the CREDENCE trial was published April 14 in The New England Journal of Medicine and presented at the International Society of Nephrology’s World Congress of Nephrology in Melbourne, Australia. Mahaffey, who is director of the Stanford Center for Clinical Research, is the study’s senior author. The lead author is Vlado Perkovic, MBBS, PhD, executive director of The George Institute for Global Health Australia, and a professor of medicine at the University of New South Wales in Sydney. Other Stanford researchers assisting in the trial were Glenn Chertow, MD, professor of medicine, and Tara Chang, MD, assistant professor of medicine, who were national co-leads; and Sun Kim, MD, associate professor of medicine, who was a site investigator.Source: http://med.stanford.edu/news/all-news/2019/04/drug-reduces-risk-of-kidney-failure-in-people-with-diabetes.html

Kenneth Mahaffey, MD

Kawasaki disease (KD) causes inflammation in arterial walls throughout the body and is most prevalent in children under 5 years of age. While most children recover, Kawasaki disease can cause coronary artery aneurisms, which can lead to thrombosis. To prevent this, many patients are prescribed anticoagulants.

However, guidelines of anticoagulant use rely on anatomical measurements alone, without considering the impact of flow patterns.

Stanford researchers Noelia Grande Gutierrez, Alison L. Marsden, and colleagues have come up with an innovative solution to this problem. They developed a computational fluid dynamics simulation that uses information derived from non-invasive vascular imaging data to provide patient-specific hemodynamic measurements. The hemodynamic variables identified by Gutierrez et al. are superior to traditionally used anatomical measurements for KD aneurysms assessment and can be used to identify aneurysmal regions at higher risk of thrombosis. In the future, personalized hemodynamics could help doctors determine how and when to use anticoagulants for Kawasaki disease patients.

The study was published in the April 15 issue of the International Journal of Cardiology.

Alison Marsden, PhD

Patient-specific hemodynamics for the treatment of Kawasaki Diseaseby Megan Mayerle, PhD

Source: http://med.stanford.edu/cvi/mission/news_center/arti-cles_announcements/application-of-patient-specific-hemodynam-ics-to-the-treatment-of.html

by Amy Jeter HansenDrug reduces risk of kidney failure in people with diabetes

Stem cell-derived cardiomyocyte tool could improve drug safetyby Amanda Chase, PhD

Patient-derived cardiomyocytes (iPSC-CMS) provide a platform for better drug screening and disease modeling, as well as and the first step toward realizing the beginnings of a more personalized approach to studying and treating heart disease. Furthermore, they can be used

to generate engineered heart tissue (EHT) Joe Zhang, PhD

to better mimic the complex environment of a living human heart. Having a highly homogeneous pool of ventricular or atrial CMs would be beneficial for applications such as: determining drug safety, cardiac evaluation, and cell therapy for heart attacks by allowing personalized cardiac repair. A team of researchers primarily affiliated with the Stanford Cardiovascular Institute sought to find a way to make the heterogenous iPSC-CMs into more homogenous population of cells. Led by first author Joe Z. Zhang, PhD., and senior author Joseph C. Wu, M.D., PhD., Director of Stanford Cardiovascular Institute, they developed an innovative tool to helps isolate specific cardiac subpopulations to generate a purer population of cells. The work was published in Cell Stem Cell. The tool developed by these researchers allows, for the first time, isolation of lineage-specific cardiovascular cells.

Source: http://med.stanford.edu/cvi/mission/news_center/articles_ announcements/stem-cell-derived-cardiomyocyte-tool-could-improve-drug-safety.html

c v i . s ta n fo rd .e d u | 11

A new role for PPARg in pulmonary arterial hypertensionby Megan Mayerle, PhD

Pulmonary arterial hypertension (PAH) is a form of pulmonary hypertension that results from the loss and narrowing of the lumen of small arteries of the lungs which causes an increase in blood pressure. Over time, this increased blood pressure can damage the heart. PAH generally affects young and otherwise healthy individuals and strikes women twice as often as men. Estimates indicate that there are between 10,000 and 20,000 PAH patients in the US.

While PAH is not yet understood at the molecular level, dysfunctional peroxisome proliferator activated receptor g (PPARg), a nuclear receptor that acts as a part of a transcription factor complex in vascular and other cell types, has been linked to many vascular diseases including PAH. Furthermore, in PAH, dysfunction of endothelial cells, the cells that line the interior of blood vessels, has been linked to the loss and narrowing of blood vessels. This leads to increased resistance to pulmonary blood flow and can culminate in heart failure and the need for a lung transplant.

In a study recently published in Cell Reports, lead author Dr. Caiyun Grace Li, corresponding author Dr. Marlene Rabinovitch, and colleagues reveal a new role for PPARg, linking it to the cellular DNA damage response and to DNA repair. In addition to providing a clearer understanding of the role that PPARg plays in PAH pathogenesis, these novel findings lay the groundwork for potential new PAH therapeutics and treatment strategies.Source: http://med.stanford.edu/cvi/mission/news_center/articles_announcements/a-new-role-for-ppar-in-pulmonary-arterial-hypertension.html

Study shows how big data can be used for personal healthby Hanae Armitage

Scientists at Stanford and their collaborators followed a cohort of more than 100 people over several years, tracking the biology of what makes them them. Now, after collecting extensive data on the group’s genetic and molecular makeup, the researchers are piecing together a new understanding of what it means to be healthy and how deviations from an individual’s norm can flag early signs of disease. The results point to a need for a paradigm shift, said Michael Snyder, PhD, professor and chair of genetics. “I would argue that the way medicine is practiced is deeply flawed and could be significantly improved through longitudinal monitoring of one’s personal health baseline,” said Snyder, who holds the Stanford W. Ascherman, MD, FACS, Professorship in Genetics. “We generally study people when they’re sick, rarely when they’re healthy, and it means we don’t really know what ‘healthy’ looks like at an individual biochemical level.”

The researchers uncovered more than 67 clinically actionable health discoveries that ranged from high blood pressure, arrhythmias, cardiomyopathy and early stage cancer detection, among others. The study intertwined data from wearable technologies, genome sequencing and microbial and molecular profiling to establish a baseline of sorts for each participant. Every person’s broad swath of data painted a picture of their biological baseline, and as scientists tracked how that picture changed, they also kept tabs on any abnormalities that could signal the development of disease.

A paper describing the research findings were published May 8 in Nature Medicine. Snyder and Francois Haddad, MD, clinical associate professor of medicine, are co-senior authors. Sophia Miryam Rose, MD, PhD, instructor of neurosurgery, and Kévin Contrepois, PhD, scientific director at Stanford Metabolic Health Center, share lead authorship.

Outside of participant health, the researchers think they may have even discovered new biomarkers for certain diseases and possibly new molecular markers for cardiovascular disease risk, among other things. For now, these are preliminary findings; the researchers will have to conduct follow-up studies to confirm their suspicions.

“I can’t tell you exactly what we’re going to find if we follow a group of 100 people over time with advanced technologies, but I can tell you we will often find things that are important for their health,” Snyder said. “Right now, we’re pretty much in the dark until we profile people, but this approach could provide us a much better view of people’s norms, what it means to be healthy and what it means when people deviate from that. Ultimately, we want to shift the practice of medicine from treating people when they are ill to a focus on keeping them healthy by predicting disease risk and catching disease before it is symptomatic.”

Source: https://med.stanford.edu/news/all-news/2019/05/study-shows-how-big-data-can-be-used-for-personal-health.html

Michael Snyder, PhD Francois Haddad, MD

Marlene Rabinovitch, MD Caiyun Grace Li, PhD

c v i . s ta n fo rd .e d u | 12

Recruitment for T32 FellowshipsMulti-Disciplinary Training Program in Cardiovascular Imaging T32 Training Grant - 2 OpeningsThe Multi-Disciplinary Training Program in Cardiovascular Imaging at Stanford is funded by the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health. With the impact of cardiovascular disease on U.S. and world health, and the rapid advances in imaging technologies and cardiovascular biology, it is critical that fellows be provided a broad, multi-disciplinary, and collaborative training program to foster their ability to translate CV imaging research into clinical applications. The program is designed to train the next generation of CV imaging investigators by exposing them to three complementary areas—clinical, engineering, and molecular imaging.http://med.stanford.edu/cvi/education/cardiovascular-imaging-t32.html

Mechanisms and Innovations in Cardiovascular Disease T32 Training Grant This program provides training in the following areas of vascular medicine and research: Vascular Reactivity and Thrombosis, Vascular Regeneration and Development, Metabolic or Lifestyle Influences on Vascular Outcomes, Proteomic Markers & Genetic Determinants of Vascular Disease, Gender and Ethnicity Differences in Vascular Disease, and Vascular Bioengineering. Twenty-nine faculty mentors from eighteen different departments within the School of Medicine and the University provide a variety of angles from which to address fundamental questions about vascular disease.http://med.stanford.edu/cvi/education/mechanisms-and-innovations-t32.html

Research Training in Myocardial Biology T32 Training Grant - 2 OpeningsThe Multi-Disciplinary Research Training Program in Myocardial Biology is funded by the National Institutes of Health to bring together post-doctoral fellows and faculty from six complementary areas – genetics and genomics, cellular signaling, molecular imaging, physiology and phenotyping, cardiac development and regeneration and outcomes research and population science. Although many possible divisions exist in the spectrum of cardiovascular investigators, one of the most discrete is the division between those researchers interested in blood vessels and those primarily interested in the biology of the heart muscle itself. Myocardial biologists at Stanford are found in diverse departments and divisions within the wider Stanford community and this provides a natural vehicle for multidisciplinary training.http://med.stanford.edu/cvmedicine/education/timbs.html

Failure to take statins leads to higher mortalityMore than a third of patients with cardiovascular disease who have been prescribed statins to reduce cholesterol failed to take them daily. Women and non-whites were least likely to take their prescriptions, as were the oldest and youngest patients.

Fatima Rodriguez, MD

Lab-grown heart cells reveal secrets of "kissing bug" diseaseby Krista Conger

People infected with the parasite Trypanosoma cruzi develop (among other symptoms) fever, aches, fatigue, diarrhea and vomiting. About 30 percent of those infected go on to develop chronic Chagas disease, which can cause long-term Adriana Bozzi, PhD

health complications including heart failure and digestive problems. Varieties of the bug are found in 28 states, mostly in the southern parts of the country. It is widespread in South America, and Chagas disease is estimated to contribute to more than 10,000 deaths each year.

Now cardiologist and stem cell researcher Joseph Wu, MD, PhD, together with visiting scholar Adriana Bozzi, PhD, have used lab-grown heart muscle cells called cardiomyocytes to investigate at a cellular level how the infection spread by the bugs affects cardiac function. They published their findings recently in Stem Cell Reports.

Source: https://scopeblog.stanford.edu/2019/05/21/lab-grown-heart-

cells-reveal-secrets-of-kissing-bug-disease/

“The take-away for clinicians is not to become complacent about stable patients with cardiovascular disease,” said Stanford cardiologist Fatima Rodriguez, MD, the lead author of a study published in JAMA Cardiology. Rodriguez and colleagues examined the health records of 347,104 patients with atherosclerotic cardiovascular disease — caused by fatty deposits in their arteries — who had been prescribed statins. Even those who were pretty good — but not perfect — at picking up their prescriptions showed some increased mortality, Rodriguez said. Stanford cardiologist Paul Heidenreich, MD, the senior author of the study, said that physicians can often do more to encourage their patients to take their medications daily.Source: Source: https://scopeblog.stanford.edu/2019/02/14/failure-to-take-statins-leads-to-higher-mortality/

by Mandy Erickson

c v i . s ta n fo rd .e d u | 13

Funding Opportunities

June 20192020 Sanofi Innovation Awards (iAwards). Eligibility: faculty with PI eligibility and CE faculty (with an approved CE faculty PI waiver) involved in multi-therapeutic areas including: immune-oncology, molecular oncology, immunology and inflammation, rare diseases, neurosciences, diabetes, and cardiovascular diseases. Deadline: June 29, 2019 to Lisa Chen at lisc@stanford.edu.

July 2019AHA Merit Award. $200,000 per year for 5 years. Eligability: Stanford tenured or tenure-track Associate Professors or higher, PhD and/or MD, PI on multiple active, national, peer-reviewed awards. Must devote 75% effort. Deadline: July 11, 2019 Letter of Intent; September 24, 2019 full proposal.

NIH Pathway to Independence Award. (Parent K99/R00 Independent Clinical Trial Required). Deadline: July 12, 2019. PA-19-129.

NIH Mentored Research Scientist Development Award. (Parent K01 - Independent Clinical Trial Not Allowed). Deadline: July 12, 2019. PA-19-126.

NIH R21 Exploratory/Developmental Research Grant. Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R21 Clinical Trial Optional). Deadline: July 16, 2019. PA-19-111.

NIH/NHLBI R34 Planning Grant. Clinical Trial Pilot Studies (R34 Clinical Trial Optional). Deadline: July 16, 2019. PAR-19-155.

NIH/NHLBI Notice of Special Interest (NOSI): Bold New Bioengineering Research for Heart, Lung, Blood and Sleep Disorders and Diseases. Area of special interest in exploring bold, new bioengineering approaches or concepts that are important to a substantive heart, lung, blood or sleep area. Applications in response to this Notice must be submitted through NIH Parent Announcement: NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed). Deadline: July 16, 2019. PA-19-053

AHA Institute for Precision Cardiovascular Medicine. AHA Grand Challenge: Precision Health and Precision Medicine. $250,000 per year for 4 years. Eligibility: Stanford faculty with PI eligibility and CE faculty (with an approved CE faculty PI waiver). Deadline: July 31, 2019.

August 2019NIH Ruth L. Kirschstein National Research Service Award (NRSA). Individual Postdoctoral Fellowship (Parent F32). Deadline: August 8, 2019. PA-19-188.

American Heart Association Postdoctoral Fellowship. Amount: $51,484 - $125,120. See guidelines for budget information. Deadline: August 15, 2019

NIH NHLBI Clinical Ancillary Studies (R01 Clinical Trial Optional). Deadline: August 24, 2019. PAR-18-643.

NIH Director’s New Innovator Award Program (DP2 Clinical Trial Optional). Supports early stage investigators of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important problems relevant to the mission of NIH. Deadline: August 26, 2019. RFA-RM-19-006.

September 2019NIH Director's Pioneer Award (DP1 Clinical Trial Optional). Amount: $700,000. Deadline: September 6, 2019. RFA-RM-19-005.

Fondation Leducq: Transatlantic Networks of Excellence in Cardiovascular and Neurovascular Research. Amount: up to $6M over 5 yrs (up to 5 to be awarded). Eligibility: Stanford faculty with PI eligibility and CE faculty (with an approved CE faculty PI waiver). Deadline: Letter of Intent (required): Sept. Paris Time (via proposal central). Full proposal (by invitation only): Feb. via proposal central.

Nina Starr Braunwald Research Award. Amount: up to $40,000 per year for 2 years. Eligibility: faculty with PI eligibility and CE faculty (with an approved CE faculty PI waiver); early-career women cardiac surgeon. Deadline: Sept. 15, 2019.

Nina Starr Braunwald Research Fellowship Award. Amount: up to $30,000 per year for 2 years. Eligibility: woman resident working in a cardiac surgical clinic or laboratory research program who has not yet completed cardiothoracic surgical training. Deadline: Sept. 15, 2019.

TSF Every Heartbeat Matters Award. Amount: $37,500. Eligibilty: faculty with PI eligibility and CE faculty (with an approved CE faculty PI waiver). Applicants must be ABTS (or equivalent) certified cardiothoracic surgeons. Deadline: Sept. 15, 2019.

NIH Director’s Transformative Research Awards (R01 Clinical Trial Optional) (no budget limit). Deadline: Sept. 20, 2019. RFA-RM-007.

c v i . s ta n fo rd .e d u | 14

National and Global Cardiovascular Conferences

JUNE 2019

American College of Cardiology Care of the Athletic Heart: From Elite to Exercise Enthusiasts. June 20-22, 2019. Heart House, Washington, DC.

23rd Annual Hypertension, Diabetes and Dsylipidemia Conference. June 21 - 23, 2019. Hyatt Place + Hyatt House Historic District, Charleston, SC.

Cardiac Rhythm Devise: Implantation, Management and Follow Up. June 21-23, 2019. Sofitel, New York, NY.

International Society for Stem Cell Research. June 26-29, 2019. Los Angeles Convention Center, Los Angeles, CA.

Heart Failure Up North: Practical Approaches to the Management of Congestive Heart Failure. June 29-30, 2019. Maddens on Gull Lake, Brainerd, Minnesota.

JULY 2019

Stanford University 27th Annual Pediatric Update and Pre-Conference: What’s New in Allergy and Pulmonology 2019. July 18-20, 2019. The Frances C. Arrillaga Alumni Center, Stanford, CA.

Current Applications and Future of Artificial Intelligence in Cardiology. July 19-20, 2019. Intercontinental San Francisco, San Francisco, CA.

Echocardiographic Symposium at Vail: State-of-the-Art Review, Live Scanning With Emphasis on Multimodality Imaging With Cardiac CT & MRI. July 22-25, 2019. Vail Marriott, Vail, CO.

American Heart Association Basic Cardiovascular Sciences Scientific Sessions. July 29-August 1, 2019. Westin Boston Waterfront, Boston, MA.

AUGUST 2019

Cardiology Update: The Heart of the Matter 2019. August 1-4, 2019. Sedona, AZ.

Success With Failure: Strategies for the Evaluation and Treatment of Heart Failure. August 2-4, 2019. The Greenbrier, White Sulphur Springs, WV.

American College of Cardiology ACC/SCAI Premier Interventional Cardiology Overview and Board Preparatory Course. August 8-11, 2019.

Cardiovascular Board Review for Initial Certification and Recertification. August 24-29, 2019. Mayo Civic Center, Rochester, MN.

SEPTEMBER 2019

American Heart Association Hypertension 2019 Scientific Sessions. September 5–8, 2019. New Orleans Marriott, New Orleans, Louisiana.

Interventional Cardiology Review Course for Boards and Recertification. September 6-8, 2019. Hilton Rochester Mayo Clinic, Rochester, MN.

Advanced Catheter Ablation: New Tips, Techniques and Technologies for Complex Arrhythmias. September 7-10, 2019. Swissotel Chicago, Chicago, IL.

American College of Cardiology 2019 Cardiovascular Service Lines 101 Webinar. 12-1 pm September 12, 2019.

Stanford University Electrophysiology in the West 2019: The Latest Advances in Arrhythmia Care. Li Ka Shing Center for Learning and Knowledge, September 13, 2019.

Cardiac Rehabilitation Workshop: The Mayo Clinic Model. September 23-25, 2019. Rochester, MN.

Advanced Cardiovascular Implantable Electronic Device (CIED) Management: Case-Based Approach. September 26-28, 2019. Siebens Building - Phillips Hall, Rochester, MN.

Challenges in Clinical Cardiology: A Case-Based Update. September 27-29, 2019. Swissotel Chicago, Chicago, IL.

OCTOBER 2019

Echo in Congenital Heart Disease: Special Emphasis on Adult Congenital Heart Disease: Including Uses of Multimodality Imaging. October 2-5, 2019. Hyatt Regency Coconut Point, Bonita Springs, FL.

American College of Cardiology Core Curriculum for the Cardiovascular Clinician. October 2- 5, 2019. Washington, DC.

American College of Cardiology Heart Valve Summit: Medical, Surgical and Interventional Decision Making. October 3- 5, 2019. Chicago, IL.

The Genetics of Heart & Vascular Disease. October 10-12, 2019. The Meritage Resort, Napa, CA.

Innovations in Atrial Fibrillation Management: Impacting Quality of Life and Stroke Risk. October 18-19, 2019. Grand Hyatt Seattle, Seattle, Washington.

Cases in Echocardiography, Cardiac CT, and MRI. October 23-26, 2019. The Meritage Resort, Napa, CA.

Vascular Biology 2019. October 27-31, 2019. Asilomar Conference Grounds, Monterey, CA.

c v i . s ta n fo rd .e d u | 15

Clinical Biomarker & Phenotyping Core Lab (BPCL)

BPCL provides quantitative assessment of clinical cardiovascular phenotypes for translational research and clinical trials. These cardiovascular phenotypes include evaluating cardiac structure and function, measuring carotid intimal thickness and arterial stiffness, and testing endothelial function and cardiopulmonary exercise testing.

In collaboration with the Human Immune Monitoring Center at Stanford and members of the Cardiovascular Institute, we also offer central blood processing and banking capabilities. In addition, we develop new biomarker platforms and imaging modalities. Contact: Francois Haddad, MD / fhaddad@stanford.edu

CVI Cores

Normal and patient-derived reprogrammed cardiomyocytes are a tremendous resource for researchers and physicians here at Stanford and around the country. Understanding the disease process directly at the population level and observing these cells as surrogates under a myriad conditions has the potential to be a game-changer for cardiovascular medical research.

To facilitate research in a dish that allows screening of new compounds or characterization of human disease phenotypes using cardiomyocytes, the Institute created a service by which de-identified peripheral blood mononuclear cell (PBMC) samples from selected patients can be sent to Stanford CVI for reprogramming free of cost.

SCVI biobank is supported in part by National Heart, Lung and Blood Institute (NHLBI) and the Stanford Cardiovascular Institute (CVI).

Stanford iPSC Biobank was recently mentioned in Nature Methods news: nature.com/nmeth/

journal/v12/n2/full/nmeth.3263.html.

Contact: Joseph Wu, MD, PhD / joewu@stanford.edu or Biobank manager, Yan Zhuge, PhD / yanzhuge@stanford.edu with any questions.

3DQ Imaging Laboratory Stanford’s 3DQ Imaging Laboratory develops new approaches to exploration, analysis and quantitative assessments of diagnostic images that result in new and/or more cost-effective diagnostic approaches, and new techniques for the design and monitoring of therapy. The lab processes over 1,200 clinical cases to deliver relevant visualization and analysis of medical imaging data at Stanford. The lab is co-directed by Dominik Fleischmann, MD, Roland Bammer, PhD and Sandy Napel, PhD. Contact: Dominik Fleischmann, MD, at d.fleischmann@stanford.edu

Stanford CVI Human iPSC Biobank Service

Cardiovascular Pharma-cology (BioADD)The Cardiovascular Pharmacology/Biomaterials and Advanced Drug Delivery (BioADD) Laboratory is a cutting edge research facility that specializes in the creation of biomaterials and drug delivery agents. The lab lends its expertise toward designing and analyzing biomaterials, developing drug delivery devices and formulations, pharmacokinetic and pharmacodynamic studies, and developing smart materials for biomedical applications. The CVI Cardiovascular Pharmacology also offers trainings and lectures.

Contact: Jayakumar Rajadas, PhD jayraja@stanford.edu

CVI Clinical Trials Core The CVI Clinical Trials Core provides full spectrum of support to CVI members and their clinical trials. The coordinators has extensive clinical research experience in both industry and academia. The team provides services and support to principal investigators and sponsors, including:

Contact: Ed Finn, Clinical Trials Manager at efin@stanford.edu

• Consultation

• Study start-up management, includingIRB applications, budget development

• Subject recruitment, site visits, andfollow-ups (AE reporting and queries)

• Data management

• Regulatory compliance and documen-tation

• Closeout

c v i . s ta n fo rd .e d u | 16

Communication is at the heart of scientific advancement and innovation. This quarter, the Stanford Cardiovascular Institute members published over 350 original manuscripts and reviews, further contributing to our understanding of cardiovascular biology and disease. Here, we highlight selected manuscripts by our members.

Member Publications

MARCHCardiac Segmental Strain Analysis in Pediatric Left Ventricular Noncompaction Cardiomyopathy. Arunamata A, Stringer J, Balasubramanian S, Tacy TA, Silverman NH, Punn R. J Am Soc Echocardiogr. 2019 Mar 26.

4-Methylumbelliferyl glucuronide contributes to hyaluronan synthesis inhibition. Nagy N, Gurevich I, Kuipers HF, Ruppert SM, Marshall PL, Xie BJ, Sun W, Malkovskiy AV, Rajadas J, Grandoch M, Fischer JW, Frymoyer AR, Kaber G, Bollyky PL. J Biol Chem. 2019 Mar 26.

Proposed achievable levels of dose and impact of dose-reduction systems for thrombectomy in acute ischemic stroke: an international, multicentric, retrospective study in 1096 patients. Guenego A, Mosimann PJ, Pereira VM, Nicholson P, Zuber K, Lotterie JA, Dobrocky T, Marcellus DG, Olivot JM, Piotin M, Gralla J, Fahed R, Wintermark M, Heit JJ, Cognard C; RADON Investigators. Eur Radiol. 2019 Mar 22.

Gene-Environment Interaction in the Era of Precision Medicine. Li J, Li X, Zhang S, Snyder M. Cell. 2019 Mar 21;177(1):38-44.

Preoperative Laboratory Studies for Pediatric Cardiac Surgery Patients: A Multi-Institutional Perspective. Jones SE, Jooste EH, Gottlieb EA, Schwartz J, Goswami D, Gautam NK, Benkwitz C, Downey LA, Guzzetta NA, Zabala L, Latham GJ, Faraoni D, Navaratnam M, Wise-Faberowski L, McDaniel M, Spurrier E, Machovec KA. Anesth Analg. 2019 Mar 14.

Short-Term Outcomes of en bloc Combined Heart and Liver Transplantation in the Failing Fontan. Vaikunth SS, Concepcion W, Daugherty T, Fowler M, Lutchman G, Maeda K, Rosenthal DN, Teuteberg J, Joseph Woo Y, Lui GK. Clin Transplant. 2019 Mar 20:e13540.

Outcomes of pulmonary artery reconstruction in Williams syndrome. Collins RT 2nd, Mainwaring RD, MacMillen KL, Hanley FL. Ann Thorac Surg. 2019 Mar 15.

Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy. Judge DP, Falk RH, Maurer MS, Shah SJ, Witteles RM, Grogan M, Selby VN, Jacoby D, Hanna M, Nativi-Nicolau J, Patel J, Rao S, Sinha U, Turtle CW, Fox JC, Heitner SB. J Am Coll Cardiol. 2019 Mar 12.

Comparing phase and electrographic flow mapping for persistent atrial fibrillation. Swerdlow M, Tamboli M, Alhusseini MI, Moosvi N, Rogers AJ, Leef G, Wang PJ, Rillig A, Brachmann J, Sauer WH, Ruppersberg P, Narayan SM, Baykaner T. Pacing Clin Electrophysiol. 2019 Mar 18.

Practice Variation in Anticoagulation Prescription and Outcomes after Device-Detected Atrial Fibrillation: Insights from the Veterans Health Administration. Perino AC, Fan J, Askari M, Heidenreich PA, Keung E, Raitt MH, Piccini JP, Ziegler PD, Turakhia MP. Circulation. 2019 Mar 17.

A Human iPSC Double-Reporter System Enables Purification of Cardiac Lineage Subpopulations with Distinct Function and Drug Response Profiles. Zhang JZ, Termglinchan V, Shao NY, Itzhaki I, Liu C, Ma N, Tian L, Wang VY, Chang ACY, Guo H, Kitani T, Wu H, Lam CK, Kodo K, Sayed N, Blau HM, Wu JC. Cell Stem Cell. 2019 Mar 6.

Human Induced Pluripotent Stem Cell Model of Trastuzumab-Induced Cardiac Dysfunction in Breast Cancer Patients. Kitani T, Ong SG, Lam CK, Rhee JW, Zhang JZ, Oikonomopoulos A, Ma N, Tian L, Lee J, Telli ML, Witteles RM, Sharma A, Sayed N, Wu JC. Circulation. 2019 Mar 14.

Bridge to Transplant with Ventricular Assist Device Support in Pediatric Patients with Single Ventricle Heart Disease. Chen S, Rosenthal DN, Murray J, Dykes JC, Almond CS, Yarlagadda VV, Wright G, Navaratnam M, Reinhartz O, Maeda K. ASAIO J. 2019 Mar 6.

Predicting Future Cardiovascular Events in Patients With Peripheral Artery Disease Using Electronic Health Record Data. Ross EG, Jung K, Dudley JT, Li L, Leeper NJ, Shah NH. Circ Cardiovasc Qual Outcomes. 2019 Mar;12(3):e004741.

Lymphatic endothelial cell calcium pulses are sensitive to spatial gradients in wall shear stress. Surya VN, Michalaki E, Fuller GG, Dunn AR. Mol Biol Cell. 2019 Mar 21;30(7):923-931.

The 2019 update of the European abdominal aortic aneurysm guidelines. Dalman RL. J Vasc Surg. 2019 Mar;69(3):633-634.

A Biocompatible Therapeutic Catheter-Deliverable Hydrogel for In Situ Tissue Engineering. Steele AN, Stapleton LM, Farry JM, Lucian HJ, Paulsen MJ, Eskandari A, Hironaka CE, Thakore AD, Wang H, Yu AC, Chan D, Appel EA, Woo YJ. Adv Healthc Mater. 2019 Mar;8(5):e1801147.

Discovery of Distinct Immune Phenotypes Using Machine Learning in Pulmonary Arterial Hypertension. Sweatt AJ, Hedlin HK, Balasubramanian V, Hsi A, Blum LK, Robinson WH, Haddad F, Hickey PM, Condliffe R, Lawrie A, Nicolls MR, Rabinovitch M, Khatri P, Zamanian RT. Circ Res. 2019 Mar 15;124(6):904-919.

Absent or Excessive Corpus Luteum Number Is Associated With Altered Maternal Vascular Health in Early Pregnancy. von Versen-Höynck F, Narasimhan P, Selamet Tierney ES, Martinez N, Conrad KP, Baker VL, Winn VD. Hypertension. 2019 Mar;73(3):680-690.

Death or resolution: the "natural history" of pulmonary hypertension in bronchopulmonary dysplasia. Altit G, Bhombal S, Hopper RK, Tacy TA, Feinstein J. J Perinatol. 2019 Mar;39(3):415-425.

Parental Acquisition of Echocardiographic Images in Pediatric Heart Transplant Patients Using a Handheld Device: A Pilot Telehealth Study. Dykes JC, Kipps AK, Chen A, Nourse S, Rosenthal DN, Selamet Tierney ES. J Am Soc Echocardiogr. 2019 Mar;32(3):404-411.

Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial. Abtan J, Ducrocq G, Steg PG, Stone GW, Mahaffey KW, Gibson CM, Hamm C, Price MJ, Prats J, Elkin S, Deliargyris EN, White HD, Menozzi A, Harrington RA, Bhatt DL; MPH on Behalf of the CHAMPION PHOENIX Investigators. Int J Cardiol. 2019 Mar 1;278:217-222.

Understanding health disparities. Stevenson DK, Wong RJ, Aghaeepour N, Angst MS, Darmstadt GL, DiGiulio DB, Druzin ML, Gaudilliere B, Gibbs RS, B Gould J, Katz M, Li J, Moufarrej MN, Quaintance CC, Quake SR, Relman DA, Shaw GM, Snyder MP, Wang X, Wise PH. J Perinatol. 2019 Mar;39(3):354-358.

Heart transplantation in two adolescents with Danon disease. Oren D, Chau P, Manning M, Kwong J, Kaufman BD, Maeda K, Rosenthal DN, Hollander SA. Pediatr Transplant. 2019 Mar;23(2):e13335.

Metformin prescription status and abdominal aortic aneurysm disease progression in the U.S. veteran population. Itoga NK, Rothenberg KA, Suarez P, Ho TV, Mell MW, Xu B, Curtin CM, Dalman RL. J Vasc Surg. 2019 Mar;69(3):710-716.e3.

Time based versus strain based myocardial performance indices in hypertrophic cardiomyopathy, the merging role of left atrial strain. Kobayashi Y, Moneghetti KJ, Bouajila S, Stolfo D, Finocchiaro G, Kuznetsova T, Liang D, Schnittger I, Ashley E, Wheeler M, Haddad F. Eur Heart J Cardiovasc Imaging. 2019 Mar 1;20(3):334-342.

c v i . s ta n fo rd .e d u | 17

APRILAthletic Remodeling in Female College Athletes: The "Morganroth Hypothesis" Revisited. Kooreman Z, Giraldeau G, Finocchiaro G, Kobayashi Y, Wheeler M, Perez M, Moneghetti K, Oxborough D, George KP, Myers J, Ashley E, Haddad F. Clin J Sport Med. 2019 May;29(3):224-231

Comparison of Patient-Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT - AF Registry. Perino AC, Shrader P, Turakhia MP, Ansell JE, Gersh BJ, Fonarow GC, Go AS, Kaiser DW, Hylek EM, Kowey PR, Singer DE, Thomas L, Steinberg BA, Peterson ED, Piccini JP, Mahaffey KW. J Am Heart Assoc. 2019 May 7;8(9):e011205.

TCF21 and AP-1 interact through epigenetic modifications to regulate coronary artery disease gene expression. Zhao Q, Wirka R, Nguyen T, Nagao M, Cheng P, Miller CL, Kim JB, Pjanic M, Quertermous T. Genome Med. 2019 May 2;11(1):23.

Trends in overall, cardiovascular and cancer-related mortality among individuals with diabetes reported on death certificates in the United States between 2007 and 2017. Kim D, Li AA, Cholankeril G, Kim SH, Ingelsson E, Knowles JW, Harrington RA, Ahmed A. Diabetologia. 2019 Apr 22.

The Impact of Prescribed Fire versus Wildfire on the Immune and Cardiovascular Systems of Children. Prunicki M, Kelsey R, Lee J, Zhou X, Smith E, Haddad F, Wu J, Nadeau K. Allergy. 2019 Apr 19.

Serial assessment of postoperative ventricular mechanics in young children with tetralogy of Fallot: Comparison of transannular patch and valve-sparing repair. Annavajjhala V, Punn R, Tacy TA, Hanley FL, McElhinney DB. Congenit Heart Dis. 2019 Apr 15

Early invasive assessment of the coronary microcirculation predicts subsequent acute rejection after heart transplantation. Okada K, Honda Y, Luikart H, Yock PG, Fitzgerald PJ, Yeung AC, Valantine HA, Khush KK, Fearon WF. Int J Cardiol. 2019 Apr 8.

Outcomes After Aortopulmonary Window for Hypoplastic Pulmonary Arteries and Dual-Supply Collaterals. Bauser-Heaton H, Ma M, McElhinney DB, Goodyer WR, Zhang Y, Chan FP, Asija R, Shek J, Wise-Faberowski L, Hanley FL. Ann Thorac Surg. 2019 Apr 10.

Physical activity, sleep and cardiovascular health data for 50,000 individuals from the MyHeart Counts Study. Hershman SG, Bot BM, Shcherbina A, Doerr M, Moayedi Y, Pavlovic A, Waggott D, Cho MK, Rosenberger ME, Haskell WL, Myers J, Champagne MA, Mignot E, Salvi D, Landray M, Tarassenko L, Harrington RA, Yeung AC, McConnell MV, Ashley EA. Sci Data. 2019 Apr 11;6(1):24.

A toolkit for genetics providers in follow-up of patients with non-diagnostic exome sequencing. Zastrow DB, Kohler JN, Bonner D, Reuter CM, Fernandez L, Grove ME, Fisk DG; Undiagnosed Diseases Network, Yang Y, Eng CM, Ward PA, Bick D, Worthey EA, Fisher PG, Ashley EA, Bernstein JA, Wheeler MT 3rd. J Genet Couns. 2019 Apr;28(2):213-228.

An orange calcium-modulated bioluminescent indicator for non-invasive activity imaging. Oh Y, Park Y, Cho JH, Wu H, Paulk NK, Liu LX, Kim N, Kay MA, Wu JC, Lin MZ. Nat Chem Biol. 2019 May;15(5):433-436

Preoperative Laboratory Studies for Pediatric Cardiac Surgery Patients: A Multi-Institutional Perspective. Jones SE, Jooste EH, Gottlieb EA, Schwartz J, Goswami D, Gautam NK, Benkwitz C, Downey LA, Guzzetta NA, Zabala L, Latham GJ, Faraoni D, Navaratnam M, Wise-Faberowski L, McDaniel M, Spurrier E, Machovec KA. Anesth Analg. 2019 May;128(5):1051-1054.

Years of Potential Life Lost Because of Cardiovascular Disease in Asian-American Subgroups, 2003-2012. Iyer DG, Shah NS, Hastings KG, Hu J, Rodriguez F, Boothroyd DB, Krishnan AV, Falasinnu T, Palaniappan L. J Am Heart Assoc. 2019 Apr 2;8(7):e010744.

Substantial Cardiovascular Morbidity in Adults With Lower-Complexity Congenital Heart Disease. Saha P, Potiny P, Rigdon J, Morello M, Tcheandjieu C, Romfh A, Fernandes SM, McElhinney DB, Bernstein D, Lui GK, Shaw GM, Ingelsson E, Priest JR. Circulation. 2019 Apr 16;139(16):1889-1899.

Nanoparticle Therapy for Vascular Diseases. Flores AM, Ye J, Jarr KU, Hosseini-Nassab N, Smith BR, Leeper NJ. Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):635-646.

Personalized medicine in cardio-oncology: the role of induced pluripotent stem cell. Sayed N, Ameen M, Wu JC. Cardiovasc Res. 2019 Apr 15;115(5):949-959.

Myocardial viability of the peri-infarct region measured by T1 mapping post manganese-enhanced MRI correlates with LV dysfunction. Tada Y, Heidary S, Tachibana A, Zaman J, Neofytou E, Dash R, Wu JC, Yang PC. Int J Cardiol. 2019 Apr 15;281:8-14

Body composition and atrial fibrillation: a Mendelian randomization study. Tikkanen E, Gustafsson S, Knowles JW, Perez M, Burgess S, Ingelsson E. Eur Heart J. 2019 Apr 21;40(16):1277-1282.

Cardiac function response to stenting in atherosclerotic renal artery disease with and without heart failure: results from the Carmel study. Kawarada O, Kume T, Zen K, Nakamura S, Hozawa K, Akimitsu T, Asano H, Ando H, Yamamoto Y, Yamashita T, Shinozaki N, Odashiro K, Sato T, Yuba K, Sakanoue Y, Uzu T, Okada K, Fitzgerald PJ, Honda Y, Yasuda S. ESC Heart Fail. 2019 Apr;6(2):319-327.

Loss of Endothelium-Derived Wnt5a Is Associated With Reduced Pericyte Recruitment and Small Vessel Loss in Pulmonary Arterial Hypertension. Yuan K, Shamskhou EA, Orcholski ME, Nathan A, Reddy S, Honda H, Mani V, Zeng Y, Ozen MO, Wang L, Demirci U, Tian W, Nicolls MR, de Jesus Perez VA. Circulation. 2019 Apr 2;139(14):1710-1724.

Repair of Untreated Older Patients With Tetralogy of Fallot With Major Aortopulmonary Collaterals. Vaikunth SS, Bauser-Heaton H, Lui GK, Wise-Faberowski L, Chan FP, Asija R, Hanley FL, McElhinney DB. Ann Thorac Surg. 2019 Apr;107(4):1218-1224.

Patient-Specific Multiscale Modeling of the Assisted Bidirectional Glenn. Shang JK, Esmaily M, Verma A, Reinhartz O, Figliola RS, Hsia TY, Feinstein JA, Marsden AL. Ann Thorac Surg. 2019 Apr;107(4):1232-1239.

An Automated Algorithm to Quantify Collagen Distribution in Aortic Wall. Nguyen DM, Wagenhäuser MU, Mehrkens D, Adam M, Tsao PS, Ramasubramanian AK. J Histochem Cytochem. 2019 Apr;67(4):267-274.

Characterization of 3-dimensional papillary muscle displacement in in vivo ovine models of ischemic/functional mitral regurgitation. Bothe W, Timek TA, Tibayan FA, Walther M, Daughters GT, Ingels NB Jr, Miller DC. J Thorac Cardiovasc Surg. 2019 Apr;157(4):1444-1449.

Cardiopulmonary-induced deformations of the thoracic aorta following thoracic endovascular aortic repair. Suh GY, Ullery BW, Lee JT, Dake MD, Fleischmann D, Cheng C. Vascular. 2019 Apr;27(2):181-189.

Quantification of cDNA on GMR biosensor array towards point-of-care gene expression analysis. Ravi N, Rizzi G, Chang SE, Cheung P, Utz PJ, Wang SX. Biosens Bioelectron. 2019 Apr 1;130:338-343.

MAY

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. White HD, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Erglis A, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lopes RD, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Sritara P, Tricoci P, Zeiher AM, Schwartz GG. Eur Heart J. 2019 May 23.

Comparison of routine and automated office blood pressure measurement. Cheng RZ, Bhalla V, Chang TI. Blood Press Monit. 2019 May 20.

Deep residual network for off-resonance artifact correction with application to pediatric body MRA with 3D cones. Zeng DY, Shaikh J, Holmes S, Brunsing RL, Pauly JM, Nishimura DG, Vasanawala SS, Cheng JY. Magn Reson Med. 2019 May 22.

Targeted Long-Read RNA Sequencing Demonstrates Transcriptional Diversity Driven by Splice-Site Variation in MYBPC3. Dainis A, Tseng E, Clark TA, Hon T, Wheeler M, Ashley E. Circ Genom Precis Med. 2019 May;12(5):e002464.

c v i . s ta n fo rd .e d u | 18

Therapeutic perspective on vascular cognitive impairment. Toyama K, Spin JM, Mogi M, Tsao PS. Pharmacol Res. 2019 May 17;146:104266.

Prehospital Phase of Acute Stroke Care: Guideline and Policy Considerations as Science and Evidence Rapidly Evolve. Harrington RA. Stroke. 2019 May 20:STROKEAHA119025584.

Proteasome-Dependent Regulation of Distinct Metabolic States During Long-Term Culture of Human iPSC-Derived Cardiomyocytes. Ebert A, Joshi AU, Andorf S, Dai Y, Sampathkumar S, Chen H, Li Y, Garg P, Toischer K, Hasenfu G, Mochly Rosen D, Wu JC. Circ Res. 2019 May 20.

Treatment of volumetric muscle loss in mice using nanofibrillar scaffolds enhances vascular organization and integration. Nakayama KH, Quarta M, Paine P, Alcazar C, Karakikes I, Garcia V, Abilez OJ, Calvo NS, Simmons CS, Rando TA, Huang NF. Commun Biol. 2019 May 7;2:170.

A Quality Bundle to Support High-Risk Pediatric Ventricular Assist Device Implantation. Knoll C, Chen S, Murray JM, Dykes JC, Yarlagadda VV, Rosenthal DN, Almond CS, Maeda K, Shin AY. Pediatr Cardiol. 2019 May 13.

Aged blood impairs hippocampal neural precursor activity and activates microglia via brain endothelial cell VCAM1. Yousef H, Czupalla CJ, Lee D, Chen MB, Burke AN, Zera KA, Zandstra J, Berber E, Lehallier B, Mathur V, Nair RV, Bonanno LN, Yang AC, Peterson T, Hadeiba H, Merkel T, Körbelin J, Schwaninger M, Buckwalter MS, Quake SR, Butcher EC, Wyss-Coray T. Nat Med. 2019 May 13.

Assessment of the Reconstructed Pulmonary Circulation With Lung Perfusion Scintigraphy After Unifocalization and Repair of Tetralogy of Fallot With Major Aortopulmonary Collaterals. Wise-Faberowski L, Irvin M, Lennig M, Long J, Nadel HR, Bauser-Heaton H, Asija R, Hanley FL, McElhinney DB. World J Pediatr Congenit Heart Surg. 2019 May;10(3):313-320.

Assembly of a GPCR-G Protein Complex. Du Y, Duc NM, Rasmussen SGF, Hilger D, Kubiak X, Wang L, Bohon J, Kim HR, Wegrecki M, Asuru A, Jeong KM, Lee J, Chance MR, Lodowski DT, Kobilka BK, Chung KY. Cell. 2019 May 16;177(5):1232-1242.e11.

A longitudinal big data approach for precision health. Schüssler-Fiorenza Rose SM, Contrepois K, Moneghetti KJ, Zhou W, Mishra T, Mataraso S, Dagan-Rosenfeld O, Ganz AB, Dunn J, Hornburg D, Rego S, Perelman D, Ahadi S, Sailani MR, Zhou Y, Leopold SR, Chen J, Ashland M, Christle JW, Avina M, Limcaoco P, Ruiz C, Tan M, Butte AJ, Weinstock GM, Slavich GM, Sodergren E, McLaughlin TL, Haddad F, Snyder MP. Nat Med. 2019 May;25(5):792-804.

Highly Efficient and Marker-free Genome Editing of Human Pluripotent Stem Cells by CRISPR-Cas9 RNP and AAV6 Donor-Mediated Homologous Recombination. Martin RM, Ikeda K, Cromer MK, Uchida N, Nishimura T, Romano R, Tong AJ, Lemgart VT, Camarena J, Pavel-Dinu M, Sindhu C, Wiebking V, Vaidyanathan S, Dever DP, Bak RO, Laustsen A, Lesch BJ, Jakobsen MR, Sebastiano V, Nakauchi H, Porteus MH. Cell Stem Cell. 2019 May 2;24(5):821-828.e5.

Athletic Remodeling in Female College Athletes: The "Morganroth Hypothesis" Revisited. Kooreman Z, Giraldeau G, Finocchiaro G, Kobayashi Y, Wheeler M, Perez M, Moneghetti K, Oxborough D, George KP, Myers J, Ashley E, Haddad F. Clin J Sport Med. 2019 May;29(3):224-231.

Drp1/Fis1 interaction mediates mitochondrial dysfunction in septic cardiomyopathy. Haileselassie B, Mukherjee R, Joshi AU, Napier BA, Massis LM, Ostberg NP, Queliconi BB, Monack D, Bernstein D, Mochly-Rosen D. J Mol Cell Cardiol. 2019 May;130:160-169.

An orange calcium-modulated bioluminescent indicator for non-invasive activity imaging. Oh Y, Park Y, Cho JH, Wu H, Paulk NK, Liu LX, Kim N, Kay MA, Wu JC, Lin MZ. Nat Chem Biol. 2019 May;15(5):433-436.

A Human iPSC Double-Reporter System Enables Purification of Cardiac Lineage Subpopulations with Distinct Function and Drug Response Profiles. Zhang JZ, Termglinchan V, Shao NY, Itzhaki I, Liu C, Ma N, Tian L, Wang VY, Chang ACY, Guo H, Kitani T, Wu H, Lam CK, Kodo K, Sayed N, Blau HM, Wu JC. Cell Stem Cell. 2019 May 2;24(5):802-811.e5.

Human-Induced Pluripotent Stem Cell Model of Trastuzumab-Induced Cardiac Dysfunction in Patients With Breast Cancer. Kitani T, Ong SG, Lam CK, Rhee JW, Zhang JZ, Oikonomopoulos A, Ma N, Tian L, Lee J, Telli ML, Witteles RM, Sharma A, Sayed N, Wu JC. Circulation. 2019 May 21;139(21):2451-2465.

Hydrogel-based delivery of Il-10 improves treatment of bleomycin-induced lung fibrosis in mice. Shamskhou EA, Kratochvil MJ, Orcholski ME, Nagy N, Kaber G, Steen E, Balaji S, Yuan K, Keswani S, Danielson B, Gao M, Medina C, Nathan A, Chakraborty A, Bollyky PL, De Jesus Perez VA. Biomaterials. 2019 May;203:52-62.

No evidence of a causal association of type 2 diabetes and glucose metabolism with atrial fibrillation. Harati H, Zanetti D, Rao A, Gustafsson S, Perez M, Ingelsson E, Knowles JW. Diabetologia. 2019 May;62(5):800-804.

Anti-human CD117 antibody-mediated bone marrow niche clearance in nonhuman primates and humanized NSG mice. Kwon HS, Logan AC, Chhabra A, Pang WW, Czechowicz A, Tate K, Le A, Poyser J, Hollis R, Kelly BV, Kohn DB, Weissman IL, Prohaska SS, Shizuru JA. Blood. 2019 May 9;133(19):2104-2108.

Tetralogy of Fallot: Everything you wanted to know but were afraid to ask. Wise-Faberowski L, Asija R, McElhinney DB. Paediatr Anaesth. 2019 May;29(5):475-482.

Accuracy of non-invasive stress testing in women and men with angina in the absence of obstructive coronary artery disease. Pargaonkar VS, Kobayashi Y, Kimura T, Schnittger I, Chow EKH, Froelicher VF, Rogers IS, Lee DP, Fearon WF, Yeung AC, Stefanick ML, Tremmel JA. Int J Cardiol. 2019 May 1;282:7-15.

A novel pacing maneuver to verify the postpacing interval minus the tachycardia cycle length while adjusting for decremental conduction: Using "dual-chamber entrainment" for improved supraventricular tachycardia discrimination. Kaiser DW, Nasir JM, Liem LB, Brodt C, Motonaga KS, Ceresnak SR, Turakhia MP, Dubin AM. Heart Rhythm. 2019 May;16(5):717-723.

c v i . s ta n fo rd .e d u | 19

Leadership

Joseph C. Wu, MD, PhDDirector, Stanford Cardiovascular Institute Simon H. Stertzer, MD, Professor of Medicine and Radiology

Robert A. Harrington, MDArthur L. Bloomfield Professor of Medicine Chair, Dept. of Medicine

Stephen J. Roth, MD, MPHProfessor and Chief, Pediatric CardiologyDirector, Children’s Heart Center

Ronald L. Dalman, MDWalter C. and Elsa R. Chidester Professor of SurgeryChief, Division of Vascular Surgery

Michael Snyder, PhDProfessor and Chair, Dept. of GeneticsDirector, Stanford Center for Genomics and Personalized Medicine

Dominik Fleischmann, MDProfessor, Dept. of RadiologyChief, Cardiovascular Imaging

Y. Joseph Woo, MDNorman E. Shumway Professor in Cardiothoracic SurgeryChair, Dept. of Cardiothoracic Surgery

Kenneth Mahaffey, MDProfessor, Dept. of MedicineVice Chair of Medicinefor Clinical Research

Alan Yeung, MDLi Ka Shing Professor of MedicineCo-Chief (Clinical), Division of Cardiovascular Medicine

Mark Nicolls, MDThe Stanford Professor of Pulmonary and Critical Care Medicine, Dept. of Medicine, Chief, Pulmonary and Critical Care Medicine

Paul Yock, MDMartha Meier Weiland Professor, Bioengineering and Medicine; and Professor, by courtesy, of Mechanical Engineering,Director, Byers Center for Biodesign

Tom Quertermous, MDWilliam G. Irwin Professor of MedicineCo-Chief (Research), Division of Cardiovascular Medicine

Marlene Rabinovitch, MDDwight and Vera Dunlevie Professor in Pediatric Cardiology

c v i . s ta n fo rd .e d u | 20

© STANFORD CARDIOVASCULAR INSTITUTE265 Camus Drive West, G1120

Stanford, CA 94305

cvi.stanford.edu